Cargando…

Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies

BACKGROUND: The safety, efficacy, pharmacokinetics, and pharmacodynamics of the anti-programmed cell death-1 antibody MEDI0680 were evaluated in a phase I, multicenter, dose-escalation study in advanced solid malignancies. METHODS: MEDI0680 was administered intravenously once every 2 weeks (Q2W) or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Naing, Aung, Infante, Jeffrey, Goel, Sanjay, Burris, Howard, Black, Chelsea, Marshall, Shannon, Achour, Ikbel, Barbee, Susannah, May, Rena, Morehouse, Chris, Pollizzi, Kristen, Song, Xuyang, Steele, Keith, Elgeioushi, Nairouz, Walcott, Farzana, Karakunnel, Joyson, LoRusso, Patricia, Weise, Amy, Eder, Joseph, Curti, Brendan, Oberst, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704567/ https://www.ncbi.nlm.nih.gov/pubmed/31439037 http://dx.doi.org/10.1186/s40425-019-0665-2

Ejemplares similares

A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma
por: Voss, Martin H., et al.
Publicado: (2022)

A Phase I study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) in combination with tremelimumab in patients with advanced solid tumors
por: Papadopoulos, Kyriakos P, et al.
Publicado: (2015)

Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study
por: Goldberg, Avram, et al.
Publicado: (2014)

Development of MEDI4736, an anti-programmed cell death ligand 1 (PD-L1) antibody, as monotherapy or in combination with other therapies in the treatment of non-small cell lung cancer (NSCLC)
por: Brahmer, Julie, et al.
Publicado: (2014)

Safety and disease response to MEDI-551, an anti-CD19 antibody, in chronic lymphocytic leukemia patients previously treated with rituximab
por: Forero, Andres, et al.
Publicado: (2013)

Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status
por: Rizvi, Naiyer, et al.
Publicado: (2015)

Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma
por: Kelly, Ronan J, et al.
Publicado: (2015)

Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors
por: Siu, Lillian, et al.
Publicado: (2020)

Medi-wiki worries?
por: Mason, Fred
Publicado: (2009)

MediNet: transfer learning approach with MediNet medical visual database
por: Reis, Hatice Catal, et al.
Publicado: (2023)

The CEA/CD3-Bispecific Antibody MEDI-565 (MT111) Binds a Nonlinear Epitope in the Full-Length but Not a Short Splice Variant of CEA
por: Peng, Li, et al.
Publicado: (2012)

Art, ciéncia i medi natural.
Publicado: (1994)

Medie and Info-pubmed: 2010 update
por: Ohta, Tomoko, et al.
Publicado: (2010)

Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors
por: Annunziata, Christina M., et al.
Publicado: (2012)

MediVisión 3.2 para Windows.

Chocolate in History: Food, Medicine, Medi-Food
por: Lippi, Donatella
Publicado: (2013)

Challenging the Cost Effectiveness of Medi-Cal Managed Care
por: Riner, R. Myles
Publicado: (2009)

Targeting CD73 in the tumor microenvironment with MEDI9447
por: Hay, Carl M., et al.
Publicado: (2016)

Improving interMediAte Risk management. MARK study
por: Martí, Ruth, et al.
Publicado: (2011)

Financial Performance and Participation in Medicaid and Medi-Cal Managed Care
por: McCue, Michael J., et al.
Publicado: (2001)

MediDial cards: a quick win for service improvement
por: Davies, Mike, et al.
Publicado: (2014)

Safety and efficacy of durvalumab (MEDI4736) in various solid tumors
por: Yang, Hui, et al.
Publicado: (2018)

Reviewing the role of healthy volunteer studies in drug development
por: Karakunnel, Joyson J., et al.
Publicado: (2018)

MEDI1873, a potent, stabilized hexameric agonist of human GITR with regulatory T-cell targeting potential
por: Tigue, Natalie J., et al.
Publicado: (2017)

New trends in model and data engineering: MEDI 2018 international workshops, DETECT, MEDI4SG, IWCFS, REMEDY, Marrakesh, Morocco, October 24-26, 2018, proceedings
por: Abdelwahed, El Hassan, et al.
Publicado: (2018)

Unraveling the pharmacokinetic interaction of ticagrelor and MEDI2452 (Ticagrelor antidote) by mathematical modeling
por: Almquist, J, et al.
Publicado: (2016)

901. MEDI8897 Prevents Serious RSV Disease in Healthy Preterm Infants
por: Pamela Griffin, Mary, et al.
Publicado: (2019)

CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas
por: Oberst, Michael D, et al.
Publicado: (2014)

MEDI: Macronutrient Extraction and Determination from invertebrates, a rapid, cheap and streamlined protocol
por: Cuff, Jordan P., et al.
Publicado: (2021)

Competition in California’s Medi-Cal Managed Care Market Assessed by Herfindahl-Hirschman Index
por: Tawil, Michael, et al.
Publicado: (2022)

Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells
por: Duhen, Rebekka, et al.
Publicado: (2021)

P537: SAFETY AND TOLERABILITY OF AZD0466 AS MONOTHERAPY FOR PATIENTS WITH ADVANCED HEMATOLOGICAL MALIGNANCIES - PRELIMINARY RESULTS FROM AN ONGOING PHASE I/II TRIAL
por: Marconi, Giovanni, et al.
Publicado: (2023)

Patterns of Medicaid Eligibility: A Sample of 408 Medi-Cal Eligibles in San Francisco, California
por: Celum, Connie L., et al.
Publicado: (1981)

MediBoost: a Patient Stratification Tool for Interpretable Decision Making in the Era of Precision Medicine
por: Valdes, Gilmer, et al.
Publicado: (2016)

Treatment Efficacy of MEDI3902 in Pseudomonas aeruginosa Bloodstream Infection and Acute Pneumonia Rabbit Models
por: Le, Hoan N., et al.
Publicado: (2019)

MediSyn: uncertainty-aware visualization of multiple biomedical datasets to support drug treatment selection
por: He, Chen, et al.
Publicado: (2017)

Adherence to Mediterranean Diet Measured through Medi-Lite Score and Obesity: A Retrospective Study
por: Dinu, Monica, et al.
Publicado: (2021)

The precision medicine process for treating rare disease using the artificial intelligence tool mediKanren
por: Foksinska, Aleksandra, et al.
Publicado: (2022)

Regular medical checkup program (in K-MEDI hub) to enhance the welfare of laboratory dogs and pigs
por: Lee, Gwang-Hoon, et al.
Publicado: (2023)

Concordance of deregulated mechanisms unveiled in underpowered experiments: PTBP1 knockdown case study
por: Gardeux, Vincent, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_sqi4128biirfmo5drbeer6slbn